A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies | MicrobiomeTrials
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2022-01-11Est. Completion: 2027-08
Enrollment target: 320 participants
Locations
Ascendis Pharma Investigational Site, Los Angeles, California, United States
Ascendis Pharma Investigational Site, Los Angeles, California, United States
Ascendis Pharma Investigational Site, Springfield, Illinois, United States
Ascendis Pharma Investigational Site, Louisville, Kentucky, United States
Ascendis Pharma Investigational Site, Boston, Massachusetts, United States
Ascendis Pharma Investigational Site, Morristown, New Jersey, United States
Ascendis Pharma Investigational Site, New York, New York, United States
Ascendis Pharma Investigational Site, Huntersville, North Carolina, United States
Ascendis Pharma Investigational Site, Canton, Ohio, United States
Ascendis Pharma Investigational Site, Cincinnati, Ohio, United States
Ascendis Pharma Investigational Site, Oklahoma City, Oklahoma, United States
Ascendis Pharma Investigational Site, Pittsburgh, Pennsylvania, United States
Ascendis Pharma Investigational Site, Nashville, Tennessee, United States
Ascendis Pharma Investigational Site, Richmond, Virginia, United States
Other microbiome trials you might be interested in